Clinically proven to improve attention function, EndeavorOTC Ⓡ is the first and only digital therapeutic cleared by FDA as an over-the-counter treatment for adults with ADHD BOSTON / Jun 18, 2024 / Business Wire / Akili , Inc. (Nasdaq: AKLI), a leading digital therapeutics company, today announced U.S. Food and Drug Administration (FDA) clearance of EndeavorOTC Ⓡ (AKL-T01) as an over-the-counter treatment for adults with... Read More

Akili to operate as wholly owned subsidiary of Virtual Therapeutics KIRKLAND, Wash. & BOSTON / May 29, 2024 / Business Wire / Virtual Therapeutics, a company focused on improving mental health at scale using engaging, immersive games, and Akili, Inc. (Nasdaq: AKLI), a leading digital therapeutics company, today announced the signing of a definitive merger agreement to form a diversified, leading digital health company. Under... Read More

Company announces full voluntary prepayment of debt and termination of Amended & Restated Loan and Security Agreement with Silicon Valley Bank Following recent restructuring, focusing efforts primarily on supporting existing customers, executing the amended agreement with Shionogi, and evaluating potential strategic alternatives BOSTON / May 14, 2024 / Business Wire / Akili, Inc. (Nasdaq: AKLI), a leading digital medicine... Read More

Shionogi amendment provides Akili with near-term cash payments and cancellation of debt obligation Company announces exploration of strategic alternatives and associated workforce reduction Company to release first quarter 2024 financial results on May 14, 2024 BOSTON / Apr 30, 2024 / Business Wire / Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today provided several corporate updates, including an... Read More

FY 2023 total revenues of $1.7M, a 420% increase over FY 2022 as EndeavorOTC Ⓡ gained traction in the market following June 2023 product release Reports fourth quarter 2023 total revenues of $749 thousand, representing 7% growth over the third quarter of 2023, and positive gross margins of 66%, representing a 6 percentage point increase over the third quarter of 2023 Akili partner Shionogi releases positive Phase 3 trial... Read More

Japanese Product Now Under Review for Nationwide Marketing Approval BOSTON / Feb 26, 2024 / Business Wire / Akili , Inc. (Nasdaq: AKLI), a leading digital medicine company, today announced that its Japanese partner Shionogi & Co. Ltd has submitted Akili’s digital therapeutic SDT-001 for marketing approval with the Ministry of Health, Labor, and Welfare. SDT-001 is the Japanese, localized version of Akili’s AKL-T01 (marketed... Read More

Plans to disclose Q4/FY 2023 financial results on February 29, 2024; CEO Matthew Franklin to participate in fireside chat at TD Cowen’s 44 th Annual Healthcare Conference on March 4, 2024 Appointed John Spinale to Board of Directors and Audit Committee; provides update regarding plans for April 17, 2024 Annual Meeting and efforts to regain compliance with Nasdaq rules BOSTON / Feb 21, 2024 / Business Wire / Akili, Inc.... Read More

Akili’s Clinically Proven Digital Medicine Now Authorized for Children 8-17, Opening Option to More Patients as Ongoing Stimulant Shortage Persists BOSTON / Dec 18, 2023 / Business Wire / Akili, Inc . (Nasdaq: AKLI), a leading digital medicine company, today announced that it has received authorization from the U.S. Food and Drug Administration (FDA) to expand the label for EndeavorRx ® from 8 to 12 year-old patients with... Read More

Reports third quarter total revenues of $702 thousand, representing more than 5x growth over the second quarter of 2023, and positive gross margins of ~60% in the quarter Company has filed EndeavorOTC with FDA as an over-the-counter treatment for adults with ADHD BOSTON / Nov 09, 2023 / Business Wire / Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today reported its financial results for the quarter ended... Read More

BOSTON / Oct 19, 2023 / Business Wire / Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will host a conference call and webcast to review its financial and operating results for the third quarter of 2023 on Thursday, November 9, 2023, at 4:30 p.m. ET. A live audio webcast of the conference call and presentation will be available at www.akiliinteractive.com under Investor Relations, Events & Presentations. An... Read More

Respondents struggle with routine tasks, career setbacks, and limited treatment options; meanwhile, managers feel unprepared to provide support BOSTON / Oct 12, 2023 / Business Wire / Akili, Inc. (Nasdaq: AKLI), the leading digital medicine company behind EndeavorOTC™ , today released results from a new study examining the ways in which ADHD impacts the U.S. workforce. Akili engaged Wakefield Research to survey 500 employees... Read More

Co-founder and CEO Eddie Martucci, Ph.D. transitions to role of Board chair; Matt Franklin, president and chief operating officer of Akili, appointed president and chief executive officer BOSTON / Oct 06, 2023 / Business Wire / Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today announced that Eddie Martucci transitioned to the role of Board chair, and Matt Franklin has been appointed to serve as president... Read More

Clinical trial data show that 83% of adults with ADHD experienced improved focus, and 73% reported improvement in quality of life after EndeavorOTC treatment Available nationwide without a prescription, EndeavorOTC users can now access their personalized Focus Score and track progress towards clinically-meaningful improvements in attention. BOSTON / Sep 21, 2023 / Business Wire / Akili, Inc. (Nasdaq: AKLI), a leading digital... Read More

Non-prescription model will increase patient access to clinically-validated non-drug treatments and reduce Akili’s reliance on intermediaries Continued growth in consumer demand and engagement for EndeavorOTC™ during its initial three months on the market affirms viability of consumer-led subscription model Leaner non-prescription operating model will support reduced operating expenses and headcount, extend cash runway into... Read More

EndeavorRx Ⓡ prescriptions in pediatric ADHD market grew 27% in Q2 2023 over Q1 2023 Company is preparing FDA submission for EndeavorOTC TM as over-the-counter treatment, following its June 2023 product release in the adult ADHD market Company reaffirms FY 2023 expense guidance of $55M - $60M of non-GAAP total operating expenses and cash runway into Q1 2025 BOSTON / Aug 10, 2023 / Business Wire / Akili, Inc. (Nasdaq: AKLI),... Read More

BOSTON / Jul 10, 2023 / Business Wire / Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will host a conference call and webcast to review its financial and operating results for the second quarter of 2023 on Thursday, August 10, 2023, at 4:30 p.m. ET. A live audio webcast of the conference call and presentation will be available at www.akiliinteractive.com under Investor Relations, Events & Presentations. An... Read More

Amid growing mental health crisis, the product release enables immediate access to non-drug treatment option as Akili prepares FDA submission Available nationwide without a prescription, clinical data shows improvements in focus in 83% of adults with ADHD BOSTON / Jun 07, 2023 / Business Wire / Akili, Inc. (Nasdaq: AKLI), a... Read More

Nearly two-thirds of adolescents saw clinically meaningful improvement in attention following treatment Improvements were nearly three times as large as those in the pivotal trial that supported EndeavorRx’s FDA authorization for children with ADHD ages 8-12 Akili has filed with FDA for potential EndeavorRx label expansion BOSTON / May 31, 2023 / Business Wire / Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company,... Read More

EndeavorRx Ⓡ prescriptions for children with ADHD increased 32% in Q1 2023 over Q4 2022 Pivotal study in adults with ADHD showed significant improvements in attention and clinical outcomes, exceeding those observed in other age groups; Akili plans to include data in FDA regulatory submission later this year BOSTON / May 11, 2023 / Business Wire / Akili, Inc . (Nasdaq: AKLI), a leading digital medicine company, today reported... Read More

Attention improved in more than 80 percent of adults with ADHD, and over one-third of participants no longer exhibited an attention deficit following treatment Improvements in attention were nearly seven times larger than those seen in the pivotal trial that supported EndeavorRx’s FDA authorization for 8-12 year olds with ADHD... Read More

BOSTON / Apr 13, 2023 / Business Wire / Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will host a conference call and webcast to review its financial and operating results for the first quarter of 2023 on Thursday, May 11, 2023, at 4:30 p.m. ET. A live audio webcast of the conference call and presentation will be available at www.akiliinteractive.com under Investor Relations, Events & Presentations. An... Read More

BOSTON / Mar 07, 2023 / Business Wire / Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today reported its financial results for the quarter and full year ended December 31, 2022, and provided an update on business progress. “We have established a focused and efficient operating model that I believe best allows us to realize our goal of making EndeavorRx part of routine clinical care,” said Eddie Martucci,... Read More

BOSTON / Feb 06, 2023 / Business Wire / Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will host a conference call and webcast to review its financial and operating results for the fourth quarter and full year of 2022 on Tuesday, March 7, 2023 at 4:30 p.m. ET. A live audio webcast of the conference call and presentation will be available at www.akiliinteractive.com under Investor Relations, Events &... Read More

Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, will participate in the Biotech Showcase and Solebury 1x1 Management Access Conference , both happening alongside the J.P. Morgan Healthcare Conference in San Francisco next week. Eddie Martucci , Akili’s Co-Founder and Chief Executive Officer, will represent the company and Digital Therapeutics Alliance (DTA) as a panelist on the Biotech Showcase Future Panel:... Read More

Attention improvements were nearly three times as large as those in the pivotal trial that served as the basis for EndeavorRx’s FDA authorization for children with ADHD ages 8-12 Study data will be used to file for EndeavorRx label expansion with FDA in 2023 Akili has stopped recruitment in separate adult ADHD trial to allow... Read More